Company intelligence / Profile preview

HelloBetter

Ownership: Private
Employees: ~150
Development stage: Other

Overview

HelloBetter has demonstrated clinical efficacy through over thirty randomized controlled trials published in peer-reviewed journals. Six of its programs are approved by Germany’s Federal Institute for Drugs and Medical Devices (BfArM) as prescription digital therapeutics (DiGA), fully reimbursed under public insurance. The company’s panic disorder program received FDA Breakthrough Device Designation in the US. Over 120,000 patients have used HelloBetter’s offerings to date.

Therapeutic areas: PsychiatryNeurologyWomen's Health
Modalities: Non-pharmacological therapy (specifically Internet-based Cognitive Behavioural Therapy and digital interventions)Device
Industry: Digital Health Medical Devices

Partnerships

Partnerships with German statutory insurers/public healthcare system via DiGA listing

Beyond the preview

Go deeper on HelloBetter.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HelloBetter.

Explore the full profile